Time‐lapse imaging points towards a non‐toxic, mainly immune‐driven mode of action of ingenol mebutate in the treatment of anogenital warts

Recently, it has been reported that ingenol mebutate (IM) is an effective treatment option for anogenital warts (AGW), inducing fast wart necrosis within 24 hours in vivo. With regard to its mode of action, IM is thought to act both as an inducer of direct cytotoxic effects and immunologic mechanisms. To distinguish whether the wart necrosis is mainly caused by cytotoxic effects, or whether immune mechanisms are leading, we used time‐lapse imaging to analyse IM‐treated warts ex vivo over 24 hours. Ex vivo IM‐treated warts, which have been detached from the immune system, did not show destructive necrosis, pointing towards a primarily immune‐driven mode of action of IM in the treatment of AGW.

[1]  P. Gerber,et al.  Ingenol mebutate for the management of genital warts in sensitive anatomic locations. , 2017, Journal of the American Academy of Dermatology.

[2]  H. Haenssle,et al.  Tumor-Preferential Induction of Immune Responses and Epidermal Cell Death in Actinic Keratoses by Ingenol Mebutate , 2016, PloS one.

[3]  S. Braun,et al.  Erfolgreiche Behandlung von perianalen Condylomata acuminata mit Ingenolmebutat , 2016, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[4]  F. Bai,et al.  Neutrophil in viral infections, friend or foe? , 2013, Virus research.

[5]  J. Lord,et al.  Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells. , 2012, Journal of drugs in dermatology : JDD.

[6]  S. Tyring,et al.  Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: rapid lesion necrosis followed by lesion-specific immune response. , 2012, Journal of the American Academy of Dermatology.

[7]  D. Kavanagh,et al.  The anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-δ dependent manner , 2008, Cancer Immunology, Immunotherapy.

[8]  D. Kavanagh,et al.  Neutrophils Are a Key Component of the Antitumor Efficacy of Topical Chemotherapy with Ingenol-3-Angelate1 , 2006, The Journal of Immunology.

[9]  P. Blumberg,et al.  Characterization of the interaction of ingenol 3-angelate with protein kinase C. , 2004, Cancer research.

[10]  W. Maśliński,et al.  Protein kinase c-dependent pathway is critical for the production of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6). , 1999, Cytokine.